Richter awarded for Cariprazine.
European Medicines Agency is not a bearer of bad news only.
August is the new date.
Slashes target price, removes Esmya from model.
Negative impact on 2017 profits.
Jefferies comment EMA probe, Q4 results.
Profit of Hungary's leading drugs maker plunges.
Sentiment to be impacted by cautionary measures.
Share price drops sharply.
Earnings report expected to show profit contraction.
One of key products under EMA investigation.
Flagship product Emsya under the microscope. Richter reacts.
After robust Q3 figures.
Profit greatly beats expectations.
Regardless of rouble trouble.
Pharma firm buys treasury shares again for HUF 370 mn.
Signs exclusive distribution agreement with Prima-Temp.
For the commercialisation of novel drug in Europe, Latin America and other markets.